Hyderabad: An expert committee of the Central Drugs Standard Control Organisation (CDSCO) is scheduled to meet on Wednesday (December 9) to review applications for the emergency-use approval of the Covid-19 vaccine developed by Pfizer, Serum Institute of India and Bharat Biotech.
Global pharma major Pfizer has said it will have differential pricing on its COVID-19 vaccine for different countries, as the company aims to make the vaccine available across the world. The company's Indian arm has sought emergency use authorisation (EUA) for the Pfizer/BioNTech vaccine against COVID-19 in the country fromthe Indian drug regulator.
The Supreme Court on Wednesday said putting up posters or signs outside the homes of Covid-positive patients, to indicate they were suffering from the disease, was no longer required unless there was the direction from a competent authority. The apex court said posters could be affixed in specific cases by authorities under the Disaster Management Act.
Delhi
New Delhi: With a high number of tests being conducted and fewer new cases reported, the average positivity rate—the proportion of samples that test positive for Covid-19—remained below 5% for the seventh day in a row on Wednesday.
Of the 75,409 tests conducted, 31,098 (41%) were done using the RT-PCR method — the gold standard for coronavirus diagnosis. Experts have warned that if the RT-PCR tests slacken, it could catch the Capital off guard if the outbreak begins resurging.